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SUMMARY
Background/Objectives—Age-related changes in blood coagulation and fibrinolysis are
associated with increased risk of thrombotic events. Inherited deficiencies of coagulation proteins,
such as factor V Leiden and prothrombin G20210A, explain a small fraction of venous
thromboembolic disease (VTE). Additional genetic factors likely underlie the etiology of VTE, some
of which may become manifest at older ages.
Methods—We tested 290 common SNPs within 51 thrombosis and inflammation genes for
association with VTE in the Cardiovascular Health Study, a large, prospective cohort of older adults
followed for up to 12 years.
Results—There were 184 VTE events that occurred at mean age of 78 years. TagSNPs within four
genes encoding factor XIII subunit A (F13A), factor VII activating protease (HABP2), protease
activated receptor -1 (F2R), and the urokinase receptor (PLAUR) showed the strongest evidence for
association with VTE, with each gene having a global p-value <0.05 and at least one tagSNP false
discovery rate (FDR) q-value <0.05. The rs3024409 variant allele of F13A1 was associated with
1.66-fold increased risk of VTE, while the minor alleles of HABP2 rs6585234 and rs3862019, F2R
rs253061 and rs153311, and PLAUR rs344782 were each associated with lower risk of VTE (hazard
ratios in the range of 0.49 to 0.66). Consistent with the observed protective association on VTE risk,
the HABP2 rs3862019 variant allele was also associated with lower activity levels of coagulation
factors VIII, IX, X, and plasminogen. We also confirm previously reported associations between
common variants of the coagulation factor II, V, VIII, XI, alpha-fibrinogen, and protein C genes and
risk of VTE.
Conclusions—These findings suggest that several novel common coagulation gene variants may
be related to risk of VTE in older adults. Further studies in older adults are needed to validate these
findings and assess functional molecular mechanisms.
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Venous thromboembolism (VTE) occurs disproportionately among older adults [1]. The
reasons likely involve increases in both intrinsic blood coagulation potential that occur with
age and presence of acquired co-morbid conditions that predispose to thrombosis, such as
obesity, surgery, cancer, and immobility.
Family studies suggest the existence of genes that jointly influence thrombosis susceptibility
and plasma coagulation and fibrinolytic factor levels [2]. The strong influence of genetic factors
on plasma coagulation factor levels persists into older adulthood [3]. Inherited deficiencies of
antithrombin, protein C, and protein S, and prothrombotic mutations such as Factor V Leiden
and prothrombin G20210A, predispose to VTE [4]; but such familial thrombophilic disorders
explain only a small fraction of VTE occurring in the community [5-7].
Recent observational studies of middle aged to older adults suggest that coagulation and
inflammation gene sequence variants that are even more common in the population (allele
frequencies in the range of 10%-40%) may contribute to VTE risk [8-10]. Whether such
common thrombosis-related gene variants influence VTE occurrence has not been previously
examined in prospective studies of community-dwelling older adults. Therefore, we screened
a large panel of common single nucleotide polymorphism (SNPs) within candidate coagulation
and inflammation genes for association with VTE in the Cardiovascular Health Study (CHS),
a large, well-characterized prospective population-based study of older adults.
METHODS
Study participants and data collection
The CHS is a prospective population-based cohort study of U.S. adult men and women 65
years and older recruited from four field centers: Forsyth County, North Carolina; Sacramento
County, California; Washington County, Maryland; and Pittsburgh, Pennsylvania [11]. Those
eligible to participate included all persons 65 years of age or older living in the household of
each individual sampled. The original cohort (n=5,201) was recruited from 1989 to 1990. A
second African-American (AA) cohort (n= 687) was recruited between 1992 and 1993. Of the
total CHS cohort (n=5,888), 4,925 participants identified themselves as European-American
(EA), 924 as AA, and 39 as “other.” Local institutional review committees approved the CHS
protocol, and all subjects gave informed consent.
VTE case ascertainment and inclusion criteria
VTE was defined as the occurrence of validated deep vein thrombosis or pulmonary embolism
from baseline through December 31, 2001, as previously reported [12] and described under
Supplemental Methods. Of the total CHS cohort (n=5,888), 206 participants developed incident
VTE during follow-up. After excluding 502 subjects who did not consent to DNA testing and/
or did not have aliquots of DNA available for genotyping, there were 5,386 CHS participants
eligible for the current study. These included 184 cases and 5,202 non-cases of VTE.
Plasma coagulation factor measurement
Fibrinogen, factor VII, and factor VIII coagulant activity were measured using citrated plasma
in 5,024 EA participants from the original CHS cohort. Factor IX activity, factor X activity,
and plasminogen levels were measured on a cross-sectional sub-sample of 340 eligible
participants from the original cohort. Plasma fibrinogen was determined using the von Clauss
method. Factor VII, VIII, IX, and X activity were measured using 1-stage clotting assays and
reported as percent of a normal plasma pool [13,14]. Plasminogen was measured by rate
chromogenic assay [15].
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Candidate gene SNP selection and genotyping
We selected 51 coagulation-, fibrinolysis-, and inflammation-related candidate genes for
analysis, as described under Supplemental Methods and summarized in Supplemental Table
1. We selected a set of tagSNPs that efficiently capture common patterns of genetic variation
in the genomic regions spanning 5 kb upstream of the transcription start site and 3 kb
downstream of the transcription end site of our genes of interest using the LDselect algorithm
[16]. SNPs were selected such that all known common variants in each gene (defined as minor
allele frequency or MAF ≥10%) are correlated with a tagSNP with r2 of >0.8 in the European
SNP discovery panels from SeattleSNPs (http://pga.mbt.washington.edu/) or International
HapMap project (hhttp://www.hapmap.org). Neither Factor V Leiden nor prothrombin
G20210A were typed as part of the current study because their allele frequencies are <10%.
For some LD bins, multiple tagSNPs were typed in the case of assay failure. These redundant
tags (r2 >0.8) were removed prior to analysis. A total of 375 SNPs with MAF 10% were
successfully genotyped across the 51 candidate genes. After removing 85 SNPs that had a pair-
wise r2 >0.8 with at least one other SNP, 290 non-redundant tagSNPs remained in the final
analytic data set. Genotyping was performed as described under Supplemental Methods.
Statistical analysis
Our underlying hypothesis was that one or more common SNPs in genes related to coagulation,
fibrinolysis, and inflammation are associated with risk of VTE in older adults. In our primary
analysis, we included all incident and recurrent cases of VTE, and restricted our analysis to
self-identified whites to minimize confounding due to population structure. We assessed the
association between each tagSNPs and time to VTE during follow-up using Cox proportional
hazards regression, minimally adjusting for age and sex. We assessed tagSNP associations with
continuous measures of plasma coagulation factors using linear regression, using appropriately
transformed dependent variable, adjusted for age and sex. For time-to-event models, covariate-
adjusted hazard ratios were estimated from the regression coefficients, assuming a constant
effect size for each additional copy of the minor allele. For autosomal markers, SNP genotype
was coded 0/1/2 the number of copies of the minor allele assuming an additive inheritance
model. For X-chromosomal markers, male genotypes were coded 0/1 and female genotypes
were coded 0/0.5/1 (because of X-chromosome inactivation in women) and the regression
model adjusted for sex. Individual SNP associations with VTE were considered nominally
significant at a p-value threshold <0.05. To formally assess the statistical significance of our
results, we accounted for multiple hypothesis testing in our primary analysis in two ways: (1)
at the level of each of the 51 candidate genes, we computed a global gene-based p-value using
a permutation-based, and (2) at the level of the 290 individual tagSNPs using the false discovery
rate (FDR) or q-value method (see Supplemental Methods).
We performed several sensitivity analyses: (a) In to addition to age and sex, Cox regression
models were adjusted for smoking, BMI, and cancer (to assess the possibility that any observed
SNP association might be mediated through other VTE risk factors). (b) We repeated our
primary analysis after excluding 384 participants who had a self-reported a history of VTE
and/or were taking warfarin anticoagulants at the time of CHS study entry. (c) We included
self-reported African-American participants, additionally adjusting for race. (d) For X-linked
genes, we confirmed any genotype-phenotype associations by additionally repeating the
regression models separately in men and women.
RESULTS
Participant characteristics
The mean age of the 5,386 eligible CHS study participants was 73 years. Fifty-eight percent
were women, and 16% were African-American. Participant baseline characteristics stratified
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by race are shown in Table 1. During a mean (median) follow-up of 9.4 (11.6) years, 184 (3%)
developed VTE. The mean age at onset of VTE was 78 years. Of the 184 VTE cases, 105 (57%)
were female, 40 (22%) were African-American, and 31 (17%) reported a previous history of
VTE. When classified according to presence or absence of precipitating risk factors, 77 VTE
events were idiopathic and 107 occurred secondary to other causes (cancer, recent trauma,
surgery, or immobility).
Candidate gene SNP associations with VTE
Of 51 candidate genes screened, 12 genes had at least one tagSNP nominally associated with
VTE risk (p <0.05), including 8 genes with multiple tagSNPs nominally associated with VTE
risk (Table 2). Four candidate genes (HABP2, F2R, PLAUR, and F13A1) had global gene-
based p-values for association with VTE that were less than 0.05, and the F8 gene had a global
p-value of 0.06. Of 290 tagSNPs tested, a total of 30 SNPs (~10%) were nominally associated
with risk of VTE.
When the individual tagSNPs were corrected for multiple comparisons using the FDR method,
6 tagSNPs were significantly associated with VTE risk at a q-value threshold of <0.20 (Table
3). The tagSNP mostly strongly associated with VTE risk was F13A1 rs3024409, located in
intron 7 of the factor XIII A subunit gene (hazard ratio = 1.66; 95%CI 1.31 - 2.11; p-value
=10−5; FDR q-value = 0.002). The minor alleles of 5 other intronic tagSNPs, including
rs3862019 and rs6585234 of the factor VII activating protease gene (FSAP) gene (HABP2),
rs253061 and rs153311 of the protease activated receptor (PAR)-1 gene (F2R), and rs344782
of the urokinase receptor gene (PLAUR), were associated with lower risk of VTE (hazard ratios
in the range of 0.49 to 0.66). None of the inflammation gene variants within our panel were
significantly associated with VTE risk.
Repeating the individual SNP association analyses by (a) restricting to those without a prior
history of VTE or baseline warfarin use, or (b) additional adjustment for BMI, smoking, and
cancer, or (c) including African-American participants did not substantively affect any of these
results. In additional analyses, there was no evidence that the SNP-associated risks of VTE
differed among those with first versus recurrent VTE, nor among those VTE cases classified
as idiopathic versus secondary to cancer, recent trauma, surgery, or immobility (data not
shown). When stratified by race, there was no evidence that the risk of VTE associated with
F13A1 rs3862019, HABP2 rs3862019, F2R rs253061, F2R rs153311, or PLAUR rs344782
differed between whites and African-Americans. In contrast, the HABP2 rs6585234 showed
little evidence of VTE association in African-Americans (HR = 1.08; 95% CI 0.68 – 1.71).
When analyzed separately by gender, the rs1800921 factor VIII variant encoding the
Glu1241Asp polymorphism was associated with a HR of 0.37 (95%CI 0.14 – 1.03) in men.
Women heterozygous for the Asp1241 variant allele had an HR of 0.80 (95%CI 0.48 – 1.35),
while women homozygous for the variant allele had an HR of 0.32 (95%CI 0.05 – 2.35).
Assessment of VTE-associated SNPs in HABP2 and F8 with coagulation factor levels
Because of its ability to activate or cleave various substrates (coagulation factor VII, pro-
urokinase, fibrinogen, and platelet derived growth factor-BB) in vitro [17], we further explored
potential mechanism underlying the observed HABP2– VTE associations by assessing
genotype associations with plasma coagulation factor levels previously measured at baseline
in CHS (Table 4). Factor VII, VIII, and fibrinogen levels were measured in the entire cohort,
while factor X, IX, and plasminogen levels were measured in a selected sample of 345 CHS
participants. The rs3862019 HABP2 SNP associated with decreased risk of VTE was
associated with lower coagulation factor VIII, IX and X activity levels, and lower plasminogen
levels, particularly among homozygotes for the rare allele. In contrast, there was no association
between rs3862019 genotype and levels of factor VII activity or fibrinogen. Since factor IX,
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X, and plasminogen were measured at baseline in only a fraction of the CHS cohort, we were
unable to assess whether the addition of these intermediate traits as covariates in the Cox
regression model results in any attenuation of the association between HABP2 genotype and
risk of VTE.
Because of the previous reported association between F8 rs1800921 and lower factor VIII
levels [18], we assessed the association between F8 genotype and factor VIII activity in CHS.
The F8 rs1800291 coding variant associated with decreased VTE occurrence was associated
with lower circulating factor VIII in both men and women (Table 4). Nonetheless, in a Cox
regression model containing both factor VIII level and F8 genotype, there was little change in
VTE risk estimate for rs1800291 when adjusted for factor VIII activity levels (HR=0.69; 95%
0.49 – 0.96; p=0.03 with factor VIII:C adjustment versus HR=0.67; 95% 0.48 – 0.94; p=0.02
without factor VIII:C adjustment).
DISCUSSION
We identified several common genetic variants associated with VTE risk in older adults.
TagSNPs within genes encoding factor XIII subunit A (F13A), factor VII activating protease
(HABP2), protease activated receptor-1 (F2R), and the urokinase receptor (PLAUR) showed
the strongest evidence for association with VTE.
Newly identified coagulation gene SNPs putatively associated with VTE risk in CHS
Upon activation by thrombin, factor XIII A catalyzes the formation of cross-links between
fibrin molecules, thus stabilizing the fibrin clot. The rs3024409 variant of the factor XIII A
subunit gene results in a G/T substitution in intron 7 and is in strong linkage disequilibrium
with at least one other known F13A1 SNP (rs3024425 in intron 8; r2=1.0). FXIIIA1 rs3024409
is not in linkage disequilibrium with the factor XIIIA Val34Leu polymorphism (rs5985) that
has been reported to be associated with a modest reduction in VTE risk [19]. In a recent nested
case-control analysis that included participants from both CHS and the Atherosclerosis Risk
in Communities (ARIC) study, Val34Leu was not significantly associated with VTE [20]. Nine
other common F13A1 variants were not associated with VTE risk in post-menopausal women
[8], but the rs3024409 and rs3024425 polymorphisms were not specifically tagged by the 9
tagSNPs assessed (maximum pair-wise r2 =0.3).
A Gly534Glu polymorphism (Marburg I) of FSAP has been associated with lower proteolytic
activity towards pro-uPA and risk of both arterial and venous thrombotic disease [17]. The
Marburg I polymorphism has a population allele frequency of <5%, and therefore was not
assessed in the current study. The HABP2 rs6585234 and rs1885436 variants are located within
introns and are in strong to moderate LD (r2>0.64) with at least 10 other common intronic
SNPs. Despite the lack of any obvious effect on HABP2 gene or FSAP protein function, the
observed association of these HABP2 intronic SNPs with levels of several intrinsic coagulation
pathway components (factors X, IX, and VIII) lend further support for a potential physiologic
role of FSAP in regulation of hemostasis and thrombosis [17].
Urokinase plasminogen activator receptor (uPAR) is a GPI-linked protein expressed on
leukocytes that mediates fibrinolysis through a urokinase-dependent mechanism. Soluble
uPAR levels are increased in patients with paroxysmal nocturnal hemoglobinuria (PNH), who
are prone to developing venous thrombosis [21]. The PLAUR rs344782 variant associated with
VTE is located in intron 1 is in perfect linkage disequilibrium (r2=1.0) with 4 other intronic
PLAUR polymorphisms: rs344787, rs344785, rs344784, and rs344783. PLAUR rs344782 and
rs344785 are located ~500 bp upstream and ~ 100 bp downstream, respectively, of a
transcription start site for an alternatively spliced PLAUR transcript.
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Protease-activated receptor 1 (PAR-1) is the main thrombin receptor on platelets and vascular
endothelial cells and is encoded by the F2R gene. The minor allele of rs153311 has been
associated with lower PAR-1 platelet receptor density and lower response to the SFLLRN
peptide agonist [22]. In the Paris Thrombosis Study, another F2R variant (the insertion allele
of the −506 I/D polymorphism) was associated with lower risk of VTE in men (odds ratio =
0.52; 95% CI 0.32 to 0.82, P<0.01), but not in women [23]. In CHS, there was little evidence
of VTE association for a SNP (rs2227750) that tags the −506 I/D polymorphism (hazard ratio
=1.15, 95%CI 0.91 – 1.44; p=0.23). However, we did find a significant gender interaction
between the F2R intron 1 rs253061 polymorphism and VTE risk in CHS [HR 0.77 (95% 0.55
– 1.09) in women and 0.38 (95% 0.23 – 0.62) in men; p for interaction = 0.02].
Results in CHS for coagulation gene SNPs previously associated with VTE
In Supplemental Table 2, we summarize the VTE association results in CHS for other
coagulation gene variants that have been reported as putative VTE susceptibility loci in other
studies. The Asp1241Glu variant of factor VIII (rs1800921) has been associated with lower
factor VIII levels [18] and also with lower risk of VTE in men but not in women [24]. In CHS,
we observed associations with lower factor VIII activity and decreased VTE risk in both sexes.
In a genome-wide screen of two combined case-control studies, SNPs in the genes encoding
antithrombin (SERPINC1), platelet collagen receptor glycoprotein VI (GP6), and factor XI
(F11) were robustly associated with risk of venous thrombosis [9]. Our results and those of
Smith et al [8] confirm the association between the F11 variant and increased risk of VTE. The
risk estimate was nearly identical across the 3 studies (~1.3 per each additional copy of the
F11 minor allele). In contrast, we did not observe significant association between VTE
occurrence and SERPINC1 rs2227589 or GP6 rs1613662 (Pro219Ser), though the risk estimate
observed in CHS for the GP6 variant was not dissimilar from that reported by Bezemer et al
[9]. Our risk estimates for the A19911G variant of the prothrombin gene (rs3136516) [25,
26], the HR2 haplotype [27] and rs3753305 and rs4524/rs932619 variants of the factor V gene
[8], and the GC promoter haplotype and rs2069915 variants of the protein C gene [8,28], were
also comparable to previous reports. In contrast, we were unable to confirm VTE associations
for haplotypes or SNPs of the protein C receptor [29,30], vitamin K epoxide reductase [31],
factor VII, interleukin-10, or interleukin 1-related genes [10,32,33].
Other data suggest a lower thrombotic risk associated with Factor V Leiden among subjects
65 and older from CHS compared to middle-aged subjects from the ARIC study [35]. On the
other hand, the risk of VTE associated with G20210A was higher in CHS (OR 2.98; 95% CI
1.00 – 8.85) than ARIC (OR 1.04; 95%CI 0.31 – 3.50) [36]. A similar pattern of association
between CHS and ARIC has been reported for the alpha-fibrinogen Thr312Ala variant [37],
which is in moderate linkage disequilibrium (r-squared 0.5) with the rs207006 variant
associated with increased risk of VTE reported here and elsewhere [8].
Study strengths and limitations
The strengths of the current analysis include a comprehensive analysis of common patterns of
genetic variation across our candidate genes and the use of a prospective study design that
included all cases (both fatal and non-fatal) that occurred during follow-up. Several potential
limitations of the current study should also be noted. Statistical power was limited to detect
modest effect sizes, even for common variants. For example, a power analysis of the primary
endpoint assuming minor allele frequency of 0.20 and an additive mode of inheritance indicates
that we have >80% power to detect a relative risk of 1.4, but only ~30% power to detect a
relative risk of 1.2. Because of the community-based study design, VTE cases that were
diagnosed and managed solely as outpatients and rapidly fatal VTE events among non-
hospitalized community residents were potentially missed. The relatively small numbers of
African-American VTE cases or those with recurrent (as opposed to first-time) VTE events
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limited our ability to assess heterogeneity of SNP effects among these subgroups. As with any
indirect association study using common tagSNPs, we cannot distinguish which SNP is the
true functional variant(s) and we also cannot exclude the possibility of associations with rare
variants within our candidate genes. It is important to note that only persons 65 years and older
are included in CHS. Certain SNPs with null findings for VTE in the current study might have
been a result of survivor bias in CHS. This may explain why we were unable to reproduce some
of the findings from previous studies that included younger VTE cases [9]. Likewise, additional
assessment of any newly observed genetic associations in CHS require additional confirmation
in independent study samples that include younger individuals in order to determine the
generalizability of our findings to the community.
In summary, our findings suggest that several common coagulation gene variants may be
related to risk of VTE in older adults. Further epidemiologic studies are needed to validate
these findings in other populations and assess the functional molecular mechanisms.
Ultimately, a better understanding of the risk factors for venous thrombosis may improve
prevention and treatment of VTE in high risk individuals and groups of patients, such as older
adults.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1






Mean age, years (range) 73 (65–98) 73 (65–93)
Female sex 2,580 (57) 523 (62)
Current smokers 497 (12) 131 (9)
Body mass index (kg/m2) 26.4 ± 4.5 28.5 ± 5.6
Diagnosis of cancer 689 (15) 74 (9)
Estrogen use* 314 (12) 37 (7)
Warfarin use 70 (2) 18 (2)
Prevalent CVD† 1,085 (24) 227 (27)
VTE event during follow-up 144 (3) 40 (5)
 First event 120 33
 Recurrent event 24 7
Data are presented as number (%) or mean ± standard deviation, unless otherwise indicated.
*
% of current estrogen use among women only.
†
Self-reported myocardial infarction, stroke, angina, transient ischemic attack, claudication, or re-vascularization procedure.
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